These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 26418145)

  • 41. Early pregnancy termination with mifepristone and misoprostol in Norway.
    Bjørge L; Johnsen SL; Midbøe G; Augestad G; Økland I; Helland H; Stray-Pedersen S; Iversen OE
    Acta Obstet Gynecol Scand; 2001 Nov; 80(11):1056-61. PubMed ID: 11703208
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mifepristone dose in the regimen with misoprostol for medical abortion.
    Marions L
    Contraception; 2006 Jul; 74(1):21-5. PubMed ID: 16781255
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Randomized trial assessing home use of two pregnancy tests for determining early medical abortion outcomes at 3, 7 and 14days after mifepristone.
    Blum J; Sheldon WR; Ngoc NT; Winikoff B; Nga NT; Martin R; Van Thanh L; Blumenthal PD
    Contraception; 2016 Aug; 94(2):115-21. PubMed ID: 27067706
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Induction of second trimester abortion (12-20 weeks) with mifepristone and misoprostol: a review of 386 consecutive cases.
    Goh SE; Thong KJ
    Contraception; 2006 May; 73(5):516-9. PubMed ID: 16627037
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Expanding medical abortion in Tunisia: women's experiences from a multi-site expansion study.
    Hajri S; Blum J; Gueddana N; Saadi H; Maazoun L; Chélli H; Dabash R; Winikoff B
    Contraception; 2004 Dec; 70(6):487-91. PubMed ID: 15541411
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Acceptability and feasibility of mifepristone medical abortion in the early first trimester in Azerbaijan.
    Louie KS; Tsereteli T; Chong E; Aliyeva F; Rzayeva G; Winikoff B
    Eur J Contracept Reprod Health Care; 2014 Dec; 19(6):457-64. PubMed ID: 25047120
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A pilot study on the combined use of letrozole, mifepristone and misoprostol in termination of first trimester pregnancy up to 9 weeks' gestation.
    Chai J; Ho PC
    Eur J Obstet Gynecol Reprod Biol; 2013 Dec; 171(2):291-4. PubMed ID: 24135383
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ability of the clinician and patient to predict the outcome of mifepristone and misoprostol medical abortion.
    Rossi B; Creinin MD; Meyn LA
    Contraception; 2004 Oct; 70(4):313-7. PubMed ID: 15451336
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Medical abortion at 9-13 weeks' gestation: a review of 1076 consecutive cases.
    Hamoda H; Ashok PW; Flett GM; Templeton A
    Contraception; 2005 May; 71(5):327-32. PubMed ID: 15854631
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Randomized, double-blind, controlled trial of mifepristone in capsule versus tablet form followed by misoprostol for early medical abortion.
    Liao AH; Han XJ; Wu SY; Xiao DZh; Xiong CL; Wu XR
    Eur J Obstet Gynecol Reprod Biol; 2004 Oct; 116(2):211-6. PubMed ID: 15358467
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Termination of early pregnancy using flexible, low-dose mifepristone-misoprostol regimens.
    Heikinheimo O; Leminen R; Suhonen S
    Contraception; 2007 Dec; 76(6):456-60. PubMed ID: 18061704
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Women's experiences of a telemedicine abortion service (up to 12 weeks) implemented during the coronavirus (COVID-19) pandemic: a qualitative evaluation.
    Boydell N; Reynolds-Wright JJ; Cameron ST; Harden J
    BJOG; 2021 Oct; 128(11):1752-1761. PubMed ID: 34138505
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of Outcomes before and after Ohio's Law Mandating Use of the FDA-Approved Protocol for Medication Abortion: A Retrospective Cohort Study.
    Upadhyay UD; Johns NE; Combellick SL; Kohn JE; Keder LM; Roberts SC
    PLoS Med; 2016 Aug; 13(8):e1002110. PubMed ID: 27575488
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Women's voices and medical abortions: A review of the literature.
    Alam B; Kaler A; Mumtaz Z
    Eur J Obstet Gynecol Reprod Biol; 2020 Jun; 249():21-31. PubMed ID: 32348948
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Providing Abortion Services in the Primary Care Setting.
    Amico JR; Cheng TL; Godfrey EM
    Prim Care; 2018 Dec; 45(4):599-613. PubMed ID: 30401344
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Barriers to accessing abortion services and perspectives on using mifepristone and misoprostol at home in Great Britain.
    Aiken ARA; Guthrie KA; Schellekens M; Trussell J; Gomperts R
    Contraception; 2018 Feb; 97(2):177-183. PubMed ID: 28941978
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Women's abortion seeking behavior under restrictive abortion laws in Mexico.
    Juarez F; Bankole A; Palma JL
    PLoS One; 2019; 14(12):e0226522. PubMed ID: 31881041
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The knowledge, acceptability, and use of misoprostol for self-induced medical abortion in an urban US population.
    Rosing MA; Archbald CD
    J Am Med Womens Assoc (1972); 2000; 55(3 Suppl):183-5. PubMed ID: 10846334
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Women's experiences with the use of medical abortion in a legally restricted context: the case of Argentina.
    Ramos S; Romero M; Aizenberg L
    Reprod Health Matters; 2015 Feb; 22(44 Suppl 1):4-15. PubMed ID: 25702064
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Progestin-based contraceptive on the same day as medical abortion.
    Park J; Robinson N; Wessels U; Turner J; Geller S
    Int J Gynaecol Obstet; 2016 May; 133(2):217-20. PubMed ID: 26868071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.